281 related articles for article (PubMed ID: 12468425)
21. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
22. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
23. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
[TBL] [Abstract][Full Text] [Related]
24. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions.
Duraiswamy J; Burrows JM; Bharadwaj M; Burrows SR; Cooper L; Pimtanothai N; Khanna R
J Virol; 2003 Jul; 77(13):7401-10. PubMed ID: 12805439
[TBL] [Abstract][Full Text] [Related]
25. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
26. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
[TBL] [Abstract][Full Text] [Related]
27. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
28. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
Wang B; Yao K; Liu G; Xie F; Zhou F; Chen Y
Cell Mol Immunol; 2009 Apr; 6(2):97-103. PubMed ID: 19403058
[TBL] [Abstract][Full Text] [Related]
29. Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.
Bryden H; MacKenzie J; Andrew L; Alexander FE; Angus B; Krajewski AS; Armstrong AA; Gray D; Cartwright RA; Kane E; Wright DH; Taylor P; Jarrett RF
Int J Cancer; 1997 Aug; 72(4):614-8. PubMed ID: 9259400
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
31. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
32. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
34. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
36. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
[TBL] [Abstract][Full Text] [Related]
37. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.
Smith C; Cooper L; Burgess M; Rist M; Webb N; Lambley E; Tellam J; Marlton P; Seymour JF; Gandhi M; Khanna R
J Immunol; 2006 Oct; 177(7):4897-906. PubMed ID: 16982932
[TBL] [Abstract][Full Text] [Related]
38. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
[TBL] [Abstract][Full Text] [Related]
39. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
40. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
